Trinity College Dublin
|As first author||46|
|As last author||47|
Navin K Verma(12)
Eugene M Dempsey(9)
J V Reynolds(9)
Anthony W Ryan(7)
Andrew W. Murphy(7)
Mary J O'Connell(6)
... and 103 others
These arethe13 unique sources for Dermot Kelleher's 149 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.
|Ireland -> Dublin City University||4|
|Ireland -> Dublin City University -> PubMed||4|
|Ireland -> Dublin Institute of Technology||1|
|Ireland -> Dublin Institute of Technology -> PubMed||1|
|Ireland -> Maynooth University||1|
|Ireland -> National University of Ireland Galway||1|
|Ireland -> National University of Ireland Galway -> PubMed||1|
|Ireland -> Royal College of Surgeons in Ireland||6|
|Ireland -> Royal College of Surgeons in Ireland -> PubMed||5|
|Ireland -> Trinity College Dublin||137|
|Ireland -> Trinity College Dublin -> PubMed||55|
|Ireland -> University College Dublin||1|
|Ireland -> University College Dublin -> PubMed||1|
A vaccine comprising a structurally modified AhpC protein for inducing immunoreactivity against Helicobacter pylori. The structurally modified AhpC protein may have a molecular weight of between about 3OkDa to about 5OkDa. A modified AhpC protein with enhanced immunogenicity and antibodies raised against a structurally modified AhpC protein are also described.
Provided herein are compounds, compositions and methods for preventing or treating gastrointestinal cancer in a mammal, wherein the method comprises delivering an effective amount of a COX-2 or a similar sulfonamide inhibitor as a prodrug or derivative thereof to the colon, wherein the COX-2 or similar inhibitor is released in- vivo.
The invention relates to the use of a certain subset of cytokine markers as prognostic variables of infection status in an individual, and especially as prognostic markers of a patients developing severe infection such as pneumonia, and respiratory tract infection following surgery. The subset of cytokine markers consists of the interleukin cytokines IL-2, IL-7, IL-23, IL-27, and IL-IO, and Interferon-? (INF?) and Tissue Necrosis Factor-a (TNFa). The markers may be employed as individual prognostic variables of infection status, or they may be used in pairs or other combinations. Generally, the abundance of the markers is correlated with infection status by means of an absolute pre-operative value of biomarker abundance, ratio's of pre-operative to post-operative biomarker abundance, or ratio values for pairs of certain biomarkers within the subset.
A method of estimating sepsis risk in an individual with infection comprises a step of assaying a biological sample from the individual for an IL-2 or IL-7 mRNA value, and correlating the mRNA value with sepsis risk. The IL-2 and IL-7 mRNA values are quantified by absolute quantification of mRNA copy number, wherein the copy numbers are normalised to a house keeping gene and corrected against a calibration curve for serial dilutions of the IL-2 and IL-7 cDNA. The method generally involves a step of assaying a biological sample from the individual for IL-2 and/or IL-7 mRNA values, optionally in combination with mRNA values for other cytokines, and correlating a sum or difference of the values with sepsis risk using a regression analysis curve against outcome.
A device comprising a plurality of sample wells wherein the device has a plurality of compartments, each compartment surrounding at least one well. The compartments are defined by compartment wall means. The compartment wall means may be associated with at least one well or the compartment wall means may be associated with a group of wells. The compartment may house an environmental buffering system.
A device (1 ) for housing a scientific sample comprising at least one sample well (2) and an on-board buffering substance (3) wherein the onboard buffering substance (3) at least partly surrounds the sample well (2). The on-board buffering substance (3) may be in the form of a matrix, such as a gel-like matrix. The device (1) may further comprise an insulating means. Also described is a substance for use in culturing and/or assaying a sample whereby the substance provides atmospheric and thermal buffering. The invention further provides a lid for a single-well or multi-well sample plate, the lid being configured to facilitate delivery of a sample through the lid into a well, and for sealing the well.
The present invention relates to a method for identifying patients who are likely to develop sepsis in response to infection, a method for monitoring the progress of sepsis in a patient and to an assay kit for identifying patients who are likely to develop sepsis and/or monitoring the progress of sepsis.
A nucleic acid sequence encoding all or part of an 18-19 kDa Helicobater pylori protein is described to which immunoreactivity is detected in H. pylori negative individuals. A process for the production of a recombinant form of this protein and its use, particularly as a vaccine to provide immunological protection against H. pylori infection are also described.
A method for quantitatively and qualitatively determining the presence of a macromolecule comprises providing nanoparticles in a buffered solution, adding a test sample to the buffered nanoparticle solution, and measuring the difference between the buffered nanoparticles in the presence and absence of the test sample. The nanoparticles are preferably less than 100 nm in size.
Therapeutic drug delivery and diagnostics systems comprise biologically active compounds associated with particulate carriers of less than 20nm. These systems can be utilised for targeted modification of growth, development and functions, such as gene expression, protein synthesis, intracellular energy production and transport mechanisms in prokaryotic and eukaryotic organisms. The systems are also applicable for controlled modification of structural and functional properties of extracellular components and tissue constituents. The characteristics of a biological site are evaluated and an entity is provided which is dependent on the site characteristics. The entity comprises nanoparticles of less than 20nm. A probe comprising nanoparticles of less than 5nm is also provided.
A vaccine for the treatment or prophylaxis of C. difficile associated disease comprises a C. difficile gene or a C. difficile peptide/polypeptide or a derivative or fragment or mutant or variant thereof which is immunogenic in humans. The gene encodes a C. difficile surface layer protein, SlpA or variant or homologue thereof. The peptide/polypeptide is a C. difficile surface layer protein, SlpA or variant or homologue thereof. The vaccine may comprise a chimeric nucleic acid sequence.
Biological assays using various constructions of biochips are disclosed to mirror in vivo situations. The biochip 50 comprises a microchannel 51 having a liquid outlet port 1, bubble release port 2 and a liquid outlet port 3 with an associated bubble release port 4. A multiplicity of tests can be performed often by coating the bore of the microchannel 50 which various adhesion mediating proteins or the use of chemoattractants. The assay assembly 60 comprises a syringe pump feeding the biochip 50. An inverted microscope 65, digital camera 66 and recorder 67 are provided. A sample liquid containing cells in suspension is injected slowly through the biochip and the effect of the assay recorded over a long period.
Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.
Here is a quick breakdown of this expert's publication history
If this is the expert you have been looking for, simply click here to make contact.